These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33720084)

  • 21. PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
    Wappenschmidt B; Wardelmann E; Gehrig A; Schöndorf T; Maass N; Bonatz G; Gassel AM; Pietsch T; Mallmann P; Weber BH; Schmutzler RK
    Hum Pathol; 2004 Oct; 35(10):1260-5. PubMed ID: 15492994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
    Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
    Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
    BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium.
    Erkanli S; Kayaselcuk F; Kuscu E; Bagis T; Bolat F; Haberal A; Demirhan B
    Int J Gynecol Cancer; 2006; 16(3):1412-8. PubMed ID: 16803539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of mutation profiles to refine the classification of endometrial carcinomas.
    McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lesions sub-diagnostic of endometrioid intra-epithelial neoplasia/atypical hyperplasia: value of morphology and immunohistochemistry in predicting neoplastic outcome.
    Wyvekens N; Mutter GL; Nucci MR; Kolin DL; Parra-Herran C
    Histopathology; 2024 Oct; 85(4):579-589. PubMed ID: 38785042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical Profiling of Endometrial Serous Carcinoma.
    Chen W; Husain A; Nelson GS; Rambau PF; Liu S; Lee CH; Lee S; Duggan MA; Köbel M
    Int J Gynecol Pathol; 2017 Mar; 36(2):128-139. PubMed ID: 27167671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry.
    Santacana M; Maiques O; Valls J; Gatius S; Abó AI; López-García MÁ; Mota A; Reventós J; Moreno-Bueno G; Palacios J; Bartosch C; Dolcet X; Matias-Guiu X
    Hum Pathol; 2014 Dec; 45(12):2394-403. PubMed ID: 25282036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.
    Matsumoto N; Manrai P; Rottmann D; Wu X; Assem H; Hui P; Buza N
    Int J Gynecol Pathol; 2023 Nov; 42(6):567-575. PubMed ID: 36730675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
    Alkushi A; Köbel M; Kalloger SE; Gilks CB
    Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
    Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
    Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
    Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Morphological diagnosis of endometrial intraepithelial neoplasia and expression of PTEN].
    Zhou WX; Liang ZY; Gao J; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2009 Jun; 38(6):393-6. PubMed ID: 19781346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
    Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
    Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
    Xiong Y; Xiong YY; Zhou YF
    Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups.
    Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C
    BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression and clinical significance of Beclin1 and PTEN in endometrial carcinoma].
    Zhao JH; Wan XY; Xie X; Zhou CY; Wu QY
    Ai Zheng; 2006 Jun; 25(6):753-7. PubMed ID: 16764775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
    Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
    J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.